Dutasteride is a synthetic 4-azasteroid, developed by GlaxoSmithKline, and it is an orally-administered, second generation inhibitor of the 5α-R enzymatic complex that leads to near-maximal Dihydrotestosterone (DHT) suppression. The compound appeared in the medical literature initially under the name GG-745, later as GI198745, and was finally named Dutasteride . Dutasteride is commercially available under the brand name Avodart® (Dutasteride 0.5 mg), containing soft capsules of a mixture of mono- and diglycerides of capric/caprylic acid. Dutasteride is soluble in organic solvents, such as ethanol (44 mg/mL), methanol (64 mg/mL), and polyethylene glycol 400 (3 mg/mL), but it is insoluble in water (<0.038 ng/mL) .
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Frye SV, Bramson HN, Hermann DJ, Lee FW, Sinhababu AK, Tian G. Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharm Biotechnol. 1998;11:393–422.
US Food Drug Administration Center for Drug Evaluation and Research. Application Number 21–319 Clinical pharmacology and biopharmaceutics review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21319_Duagen_biopharmr_P1.pdf. Accessed 4 Mar 2013.
Tian G, Mook RA Jr, Moss ML, Frye SV. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry. 1995;34(41):13453–9.
Frye SV. Discovery and clinical development of Dutasteride, a potent dual 5alpha-reductase inhibitor. Curr Top Med Chem. 2006;6(5):405–21.
Foley CL, Kirby RS. 5 Alpha-reductase inhibitors: what’s new? Curr Opin Urol. 2003;13(1):31–7.
Stuart JD, Lee FW, et al. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 5steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and Finasteride in the rat. Biochem Pharmacol. 2001;62(7):933–42.
Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4 Pt 1):1399–403.
Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology. 1996;193(3):177–84.
Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 1995;105(2):209–14.
Olsson Gisleskog P, Hermann D, Hammarlund-Udenaes M, Karlsson MO. Validation of a population pharmacokinetic/pharmacodynamic model for 5alpha-reductase inhibitors. Eur J Pharm Sci. 1999;8(4):291–9.
Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002;19(6):413–25.
Andriole G, Ray P, Humphrey P, Gleave M, Rittmaster R. The impact of Dutasteride , a novel dual 5α-reductase inhibitor on both serum and intraprostatic androgens. Abstract presented at the 18th Congress of the European Association of Urology; Madrid, Spain; 12–15 March 2003.
Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther. 1998;64(6):636–47.
Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor Dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44(1):82–8.
Jacobsen SJ, Cheetham TC, Haque R, Shi JM, Loo RK. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA. 2008;300(14):1660–4.
Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–84.
GlaxoSmithKline. Prescribing information: Avodart (Dutasteride) soft gelatin capsules. Triangle Park: GlaxoSmith-Kline; 2004.
Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463–85.
Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (Dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol. 1999;47(1):53–8.
Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496–502.
Cai G, Thiessen JJ, Baidoo CA, Fossler MJ. Operating characteristics of a partial-block randomized crossover bioequivalence study for dutasteride, a drug with a long half-life: investigation through simulation and comparison with final results. J Clin Pharmacol. 2010;50(10):1142–50.
GlaxoSmithKline UK. Avodart: summary of prescribing information. https://www.medicines.org.uk/emc
Paśko P, Rodacki T, Domagała-Rodacka R, Owczarek D. Interactions between medications employed in treating benign prostatic hyperplasia and food - a short review. Biomed Pharmacother. 2016;83:1141–5.
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–41.
Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004;63(4):709–15.
Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor Dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46(4):488–94.
Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS, Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of Dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–23.
Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–8.
Choi GS, Kim JH, Oh SY, Park JM, Hong JS, Lee YS, Lee WS. Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of androgenetic alopecia. Ann Dermatol. 2016;28(4):444–50.
Christian JC, Kang KW. Efficiency of human monozygotic twins in studies of blood lipids. Metabolism. 1972;21(8):691–9.
Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol. 2007;6(1):9–13.
Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, Barnes A, Ferron-Brady G, Chetty D. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–98.
Tsunemi Y, Irisawa R, Yoshiie H, Brotherton B, Ito H, Tsuboi R, Kawashima M, Manyak M, ARI114264 Study Group. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016;43(9):1051–8.
Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, Bartoletti R. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4(6):1708–12.
Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, Park KC, Huh CH. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351–7.
Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83(1):47–54.
Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JK. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res. 1997;57(6):1020–2.
Rajender S, Vijayalakshmi K, Pooja S, Madhavi S, Paul SF, Vettriselvi V, Shroff S, Singh L, Thangaraj K. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. J Androl. 2009;30(6):703–10.
Chung HC, Lee S, Lee WS. Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients. J Dermatol. 2017;44(12):1408–9.
Vañó-Galván S, et al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study. Dermatol Ther. 2020;33(1):e13182.
Blumeyer A, Tosti A, et al. European Dermatology Forum (EDF). Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9(Suppl 6):S1–57.
Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. J Eur Acad Dermatol Venereol. 2018;32(1):11–22.
Camacho F, Tosti A. Tratamiento médico de las alopecias femeninas. Monogr Dermatol. 2005;18:92–117.
Camacho F. La pérdida del cabello en la mujer. In: Grimalt R, editor. Cuidemos de nuestro pelo. Barcelona: Farmalia Com. Ed; 2007. p. 61–103.
Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4(5):637–40.
Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014;80(6):521–5.
Georgala S, Katoulis AC, Befon A, Danopoulou I, Georgala C. Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride. J Am Acad Dermatol. 2009;61(1):157–8.
Tan KT, Messenger AG. Frontal fibrosing alopecia: clinical presentations and prognosis. Br J Dermatol. 2009;160(1):75–9.
Katoulis A, Georgala BE, Papadavid E, Kalogeromitros D, Stavrianeas N. Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus. J Eur Acad Dermatol Venereol. 2009;23(5):580–2.
Epstein ES. Finasteride and prostate cancer. Hair Transplant Forum Int. 2011;21(5):144–7.
GlaxoSmithKline protocol ΑRI40001.
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108(3):388–94.
Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64(3):537–41.
Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol. 2005;7(4):203–10.
Andriole G, Bostwick D, REDUCE Study Group, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172(4 Pt 1):1314–7.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202.
Lacy JM, Kyprianou N. A tale of two trials: the impact of 5α-reductase inhibition on prostate cancer (Review). Oncol Lett. 2014;8(4):1391–6.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31.
Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55(6):367–79.
Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012;66(11):1052–5.
Gupta AK, Carviel J, MacLeod MA, Shear N. Assessing finasteride-associated sexual dysfunction using the FAERS database. J Eur Acad Dermatol Venereol. 2017;31(6):1069–75.
Said MA, Mehta A. The impact of 5α-reductase inhibitor use for male pattern hair loss on men’s health. Curr Urol Rep. 2018;19(8):65.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872–84.
Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554–66.
Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011;8(11):3066–74.
Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection. Curr Pharm Des. 2005;11(31):4041–6.
Chi BH, Kim SC. Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean J Urol. 2011;52(9):632–6.
Traish A, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30(3)
Na Y, Ye Z, Zhang S, Chinese Dutasteride Phase III Trial (ARIA108898) Study Group. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension. Clin Drug Investig. 2012;32(1):29–39.
Liu L, Zhao S, Li F, Li E, Kang R, Luo L, Luo J, Wan S, Zhao Z. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016;13(9):1297–310.
Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, Sforza A, Mannucci E, Maggi M. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5(4):671–8.
Tsai TF, Choi GS, Kim BJ, Kim MB, Ng CF, Kochhar P, Jasper S, Brotherton B, Orban B, Lulic Z. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. J Dermatol. 2018;45(7):799–804.
Lee S, Lee YB, Choe SJ, Lee WS. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. Acta Derm Venereol. 2019;99(1):12–7.
Traish AM. Negative impact of testosterone deficiency and 5α-reductase inhibitors therapy on metabolic and sexual function in men. Adv Exp Med Biol. 2017;1043:473–526.
Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659–65.
Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56–62.
Russell DW, Berman DM, Bryant JT, Cala KM, Davis DL, Landrum CP, Prihoda JS, Silver RI, Thigpen AE, Wigley WC. The molecular genetics of steroid 5 alpha-reductases. Recent Prog Horm Res. 1994;49:275–84.
Nguyen DD, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, Trinh QD. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2021;157(1):35–42.
Thiboutot D, Bayne E, Thorne J, Gilliland K, Flanagan J, Shao Q, Light J, Helm K. Immunolocalization of 5alpha-reductase isozymes in acne lesions and normal skin. Arch Dermatol. 2000;136(9):1125–9.
Sharma P, Jain D, Maithani M, Mishra SK, Khare P, Jain V, Singh R. Development and characterization of dutasteride bearing liposomal systems for topical use. Curr Drug Discov Technol. 2011;8(2):136–45.
Xie X, Yang Y, Chi Q, Li Z, Zhang H, Li Y, Yang Y. Controlled release of dutasteride from biodegradable microspheres: in vitro and in vivo studies. PLoS One. 2014;9(12):e114835.
Madheswaran T, Baskaran R, Sundaramoorthy P, Yoo BK. Enhanced skin permeation of 5α-reductase inhibitors entrapped into surface-modified liquid crystalline nanoparticles. Arch Pharm Res. 2015;38(4):534–42.
Madheswaran T, Baskaran R, Yoo BK, Kesharwani P. In vitro and in vivo skin distribution of 5α-reductase inhibitors loaded into liquid crystalline nanoparticles. J Pharm Sci. 2017. pii: S0022–3549(17)30485–9
Noor NM, Sheikh K, Somavarapu S, Taylor KMG. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery. Eur J Pharm Biopharm. 2017;117:372–84.
Ushirobira CY, Afiune LAF, Pereira MN, Cunha-Filho M, Gelfuso GM, Gratieri T. Dutasteride nanocapsules for hair follicle targeting: Effect of chitosan-coating and physical stimulus. Int J Biol Macromol. 2020;151:56–61.
Noor NM, Abdul-Aziz A, Sheikh K, Somavarapu S, Taylor KMG. In vitro performance of dutasteride-nanostructured lipid carriers coated with lauric acid-chitosan oligomer for dermal delivery. Pharmaceutics. 2020;12(10):994.
Park SJ, Choo GH, Hwang SJ, Kim MS. Quality by design: screening of critical variables and formulation optimization of Eudragit E nanoparticles containing dutasteride. Arch Pharm Res. 2013;36(5):593–601.
Kim MS, Ha ES, Choo GH, Baek IH. Preparation and in vivo evaluation of a dutasteride-loaded solid-supersaturatable self-microemulsifying drug delivery system. Int J Mol Sci. 2015;16(5):10821–33.
Beak IH, Kim MS. Improved supersaturation and oral absorption of Dutasteride by amorphous solid dispersions. Chem Pharm Bull (Tokyo). 2012;60(11):1468–73.
Kim MS. Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs. Artif Cells Nanomed Biotechnol. 2013;41(6):363–7.
Choo GH, Park SJ, Hwang SJ, Kim MS. Formulation and in vivo evaluation of a self-microemulsifying drug delivery system of dutasteride. Drug Res (Stuttg). 2013;63(4):203–9.
Kim MS. Evaluation of in vitro dissolution and in vivo oral absorption of dutasteride-loaded eudragit E nanoparticles. Drug Res (Stuttg). 2013;63(6):326–30.
El-Komy M, Hassan A, Tawdy A, Solimon M, Hady MA. Hair loss at injection sites of mesotherapy for alopecia. J Cosmet Dermatol. 2017;16(4):e28–30.
Afiune LAF, Ushirobira CY, Barbosa DPP, de Souza PEN, Leles MIG, Cunha-Filho M, Gelfuso GM, Soler MAG, Gratieri T. Novel iron oxide nanocarriers loading finasteride or dutasteride: Enhanced skin penetration for topical treatment of alopecia. Int J Pharm. 2020;587:119709.
Mysore V. Mesotherapy in management of hairloss - is it of any use? Int J Trichol. 2010;2(1):45–6.
Kadry R, Hamadah I, Al-Issa A, Field L, Alrabiah F. Multifocal scalp abscess with subcutaneous fat necrosis and scarring alopecia as a complication of scalp mesotherapy. J Drugs Dermatol. 2008;7(1):72–3.
Abdallah MA, El-Zawahry KA, Besar HA. Mesotherapy using dutasteride-containing solution in male pattern hair loss: a controlled pilot study. J Pan-Arab League Dermatol. 2009;20:137–45.
Moftah N, Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, Ibrahim M. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27(6):686–93.
Sobhy N, Aly H, Shafee AE, Deeb ME. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatol Online. 2013;4(1):40–5.
Saceda-Corralo D, Rodrigues-Barata AR, Vañó-Galván S, Jaén-Olasolo P. Mesotherapy with dutasteride in the treatment of androgenetic alopecia. Int J Trichology. 2017;9(3):143–5.
Moftah N, Mubarak R, Abdelghani R. Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection in patients with female pattern hair loss; a prospective cohort study. J Dermatolog Treat. 201;32(7):827–36.
Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, de León-Gutiérrez H, Ocampo-Garza SS, Gómez-Flores M, Grimalt R. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020;6(6):338–45.
Boyapati A, Sinclair R. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia. Jun: Australas J Dermatol; 2012.
Bayne EK, Flanagan J, et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol. 1999;141(3):481–91.
Pindado-Ortega C, Saceda-Corralo D, Fernández-Nieto D, Jiménez-Cauhé J, Ortega-Quijano D, Moreno-Arrones ÓM, Vañó-Galván S. Prescribing habits for androgenic alopecia among dermatologists in Spain in 2019-2020: a cross-sectional study. Skin Appendage Disord. 2020;6(5):283–6.
Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019;14:399–406.
Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186(4170):1213–5.
Imperato-McGinley J, Peterson RE, Gautier T, Sturla E. Male pseudohermaphroditism secondary to 5 alpha-reductase deficiency—a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity. J Steroid Biochem. 1979;11(1B):637–45.
Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974;291(18):944–9.
Rhie A, Son HY, Kwak SJ, Lee S, Kim DY, Lew BL, Sim WY, Seo JS, Kwon O, Kim JI, Jo SJ. Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia. PLoS One. 2019;14(9):e0222533.
Rittmaster RS. Finasteride. N Engl J Med. 1994;330(2):120–5.
Sudduth SL, Koronkowski MJ. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy. 1993;13(4):309–25.
Burinsky DJ, Williams JD, Thornquest AD Jr, Sides SL. Mass spectral fragmentation reactions of a therapeutic 4-azasteroid and related compounds. J Am Soc Mass Spectrom. 2001;12(4):385–98.
Evans HC, Goa KL. Dutasteride. Drugs Aging. 2003;20(12):905–16.
Dutasteride tablets approved draft labeling. Application number 21–319.
Shin SY, Shin YH, Lee SW, Shin JY, Kim CH. Blood donors on teratogenic drugs and donor deferral periods in a clinical situation. Vox Sang. 2012;102(4):362–4.
Mahendroo MS, Russell DW. Male and female isoenzymes of steroid 5alpha-reductase. Rev Reprod. 1999;4(3):179–83.
Manabe M, Tsuboi R, Itami S, Drafting Committee for the Guidelines for the Diagnosis and Treatment of Male- and Female-Pattern Hair Loss, et al. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. J Dermatol. 2018;45(9):1031–43. https://doi.org/10.1111/1346-8138.14470.
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Anastassakis, K. (2022). Dutasteride. In: Androgenetic Alopecia From A to Z . Springer, Cham. https://doi.org/10.1007/978-3-031-08057-9_3
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-08056-2
Online ISBN: 978-3-031-08057-9